Combined lanreotide autogel and temozolomide in progressive neuroendocrine tumours: an interim safety analysis of the SONNET study

Hoersch D, Raderer M, Lahner H, Rinke A, Denecke T, Koch A, Raspel A, Naschold B, Houchard A, Pavel ME (2017)

Publication Type: Conference contribution

Publication year: 2017

Journal

Oncology Research and Treatment Karger Publishers

Book Volume: 40

Pages Range: 238-238

Authors with CRIS profile

Marianne Ellen Pavel Professur für Endokrinologie

Involved external institutions

Universitätsklinikum Essen DE Germany (DE) Charité - Universitätsmedizin Berlin DE Germany (DE) Vienna General Hospital / Allgemeines Krankenhaus der Stadt Wien (AKH) AT Austria (AT) Zentralklinikum Bad Berka DE Germany (DE) Universitätsklinikum Gießen und Marburg (UKGM) DE Germany (DE) Ipsen Pharma GmbH DE Germany (DE)

How to cite

APA:

Hoersch, D., Raderer, M., Lahner, H., Rinke, A., Denecke, T., Koch, A.,... Pavel, M.E. (2017). Combined lanreotide autogel and temozolomide in progressive neuroendocrine tumours: an interim safety analysis of the SONNET study. (pp. 238-238).

MLA:

Hoersch, D., et al. "Combined lanreotide autogel and temozolomide in progressive neuroendocrine tumours: an interim safety analysis of the SONNET study." 2017. 238-238.

BibTeX: Download